Weight and metabolic changes in patients with schizophrenia treated with paliperidone palmitate 6-month formulation versus paliperidone palmitate 3-month formulation: a post-hoc analysis.
Mark Guirguis, Robert Karl Knight, Panna Sanga et al.
✦ AI-curated · Sources linked
In 30 seconds
This post-hoc analysis of a randomized controlled trial evaluated the effects of paliperidone palmitate 6-month formulation (PP6M) versus 3-month formulation (PP3M) on weight and metabolic parameters in patients with schizophrenia. Results indicated that PP6M was associated with numerically less weight gain and more favorable changes in blood lipids, particularly in younger patients. The study spanned 36 months, including a 12-month double-blind phase and a 24-month extension.
Key findings
- Participants treated with PP6M showed numerically less weight gain compared to PP3M during the 12-month phase.
- The proportion of participants with abnormal weight change (≥7% change) did not significantly differ between groups.
- Numerical improvements in fasting blood lipids were observed in the PP6M group.
- Weight differences were more pronounced in younger patients aged 18-25 years.
Why it matters
Understanding the metabolic effects of long-acting injectable antipsychotics is crucial for managing weight gain and metabolic syndrome in patients with schizophrenia, particularly in younger populations who may be more vulnerable to these side effects.
What to keep in mind
The study was a post-hoc analysis and not powered to test weight and metabolic changes, limiting statistical rigor.